MiR-494-3p Regulates Cellular Proliferation, Invasion, Migration, and Apoptosis by PTEN/AKT Signaling in Human Glioblastoma Cells
Overview
Molecular Biology
Neurology
Authors
Affiliations
Malignant gliomas are the most common primary brain tumors, and the molecular mechanisms involving their progression and recurrence are still largely unclear. Substantial data indicate that the oncogene miR-494-3p is significantly elevated in gliomas, but the molecular functions of miR-494-3p in gliomagenesis are largely unknown. The present study aimed to explore the role of miR-494-3p and its molecular mechanism in human brain gliomas, malignant glioma cell lines, and cancer stem-like cells. The expression level of miR-494-3p in 48 human glioma issues and 8 normal brain tissues was determined using stem-loop real-time polymerase chain reaction (PCR). To study the function of miR-494-3p inhibitor in glioma cells, the miR-494-3p inhibitor lentivirus was used to transfect glioma cells. Transwell invasion system was used to estimate the effects of miR-494-3p inhibitor on the invasiveness of glioma cells. A mouse model was used to test the effect of miR-494-3p inhibitor on glioma proliferation and invasion in vivo. Results showed that the expression of miR-494-3p in human brain glioma tissues was higher than in normal brain tissues. Downregulated expression of miR-494-3p can inhibit the invasion and proliferation and promote apoptosis in glioma cells. Quantitative reverse transcription PCR and Western blotting analysis revealed that the expression of PTEN was increased after downexpression of miR-494-3p in glioma cells (U87 and U251). miR-494-3p inhibitor could prevent migration, invasion, proliferation, and promote apotosis in gliomas through PTEN/AKT pathway. Therefore, the study results have shown that miR-494-3p may act as a therapeutic target in gliomas.
Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.
Norollahi S, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S, Rashidy-Pour A, Samadani A J Egypt Natl Canc Inst. 2024; 36(1):33.
PMID: 39465481 DOI: 10.1186/s43046-024-00240-4.
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
Inocencio J, Mitrasinovic S, Asad M, Parney I, Zang X, Himes B Front Immunol. 2024; 15:1424396.
PMID: 39346924 PMC: 11427296. DOI: 10.3389/fimmu.2024.1424396.
Correlation of PTEN signaling pathway and miRNA in breast cancer.
Mohammadi M, Fazilat A, Mamalo A, Ojarudi M, Hemmati-Dinarvand M, Beilankouhi E Mol Biol Rep. 2024; 51(1):221.
PMID: 38281224 DOI: 10.1007/s11033-023-09191-w.
Myricetin suppresses traumatic brain injury-induced inflammatory response via EGFR/AKT/STAT pathway.
Wang C, Ouyang S, Zhu X, Jiang Y, Lu Z, Gong P Sci Rep. 2023; 13(1):22764.
PMID: 38123650 PMC: 10733425. DOI: 10.1038/s41598-023-50144-x.
Role of microRNA-494 in tumor progression.
Maharati A, Akhlaghipour I, Taghehchian N, Yazdi Z, Moghbeli M Am J Transl Res. 2023; 15(11):6342-6361.
PMID: 38074823 PMC: 10703645.